Many swings on a particular chart tend to be similar to others.
Until Trump stops playing sports talk radio and the latest health care debate is finished, nothing will be done on tax reform.
Winning FDA approval isn't always a win.
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
The charts don't look positive for drug company Eli Lilly.
The indices may need a rest, but stock-pickers have an edge.
The path of least resistance for LLY is lower.
There are some bearish signs developing for the stock.
But longs should consider raising sell stops to $79 from $68.
A retest of MYL's recent low is an important area.

Columnist Conversations

there is some very heavy selling today and poor price action in Facebook today.  in the first hour the st...
Stock has been roasted last five trading sessions. Time to rotate into Ford ahead of big CEO long-term plan re...
Equity futures were up slightly just before 9:30 PM Sunday night.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.